Eli Lilly’s tirzepatide achieved superior weight loss compared to placebo at 72 weeks of treatment in results from SURMOUNT-2.
The study met both co-primary objectives and all key secondary objectives for tirzepatide compared to placebo for both estimands. Those taking tirzepatide lost up to 15.7% (34.4lb or 15.6kg) of body weight for the efficacy estimand.
SURMOUNT-2 is the second global Phase III clinical trial that evaluated the efficacy and safety of tirzepatide for chronic weight management. The trial evaluated 938 adult participants with obesity or overweight and type 2 diabetes.
“Obesity is a difficult to manage disease, and it’s even more difficult for people living with type 2 diabetes,” said Dr Kunal Gulati, Executive Director Diabetes Medical Affairs, Lilly Northern Europe. “The data from SURMOUNT-2 show that trial participants achieved average weight reductions of 13.4% on tirzepatide 10mg and 15.7% on 15mg compared to 3.3% on placebo. Preventing obesity is a key focus but it’s also vitally important that we continue to develop future treatments for obesity.”
Tirzepatide also met all key secondary objectives, which included reduction in HbA1C and other cardiometabolic parameters. 41.4% (10mg) and 51.8% (15mg) of people taking tirzepatide achieved at least 15% body weight reduction compared to 2.6% of those taking placebo. Reduction in HbA1C compared to placebo was similar to the SURPASS trials in adults with type 2 diabetes.
Based on these results, Lilly plans to complete the US submission for tirzepatide in adults with obesity or overweight with weight-related co-morbidities in the coming weeks and UK submission will follow.
